Panmure Gordon (UK) Limited, an exempt principal trader, has disclosed its dealings in the securities of Allergy Therapeutics plc. On August 15, 2023, Panmure Gordon purchased 200,000 0.1p ordinary shares at a price of 0.02415 per unit and sold 63,886 0.1p ordinary shares at a price of 0.02527 per unit. No cash-settled derivative transactions or stock-settled derivative transactions were reported. There were no indemnity or option arrangements, agreements, or understandings related to relevant securities. The disclosure was made in accordance with Rule 8 of the Takeover Code.